Swipe om te navigeren naar een ander artikel
The members of the BSRBR Control Centre Consortium are detailed in the Appendix.
Comparative evidence regarding the responsiveness of the EQ-5D and SF-6D in arthritis patients is conflicting and insufficient across the range of disease severity. We examined the comparative responsiveness of the EQ-5D and SF-6D in cohorts of patients with early inflammatory disease through to severe rheumatoid arthritis (RA).
Responsiveness was tested using the effect size (ES) and standardised response mean (SRM). Correlation of change in EQ-5D and SF-6D with disease specific measures was tested using Pearson correlations and the Steiger’s Z test. Treatment response and self-reported change were used as anchors of important change.
The EQ-5D was more responsive to deterioration (ES ratio (EQ-5D/SF-6D): 1.6–3.0) and the SF-6D more responsive to improvement (ES ratio (SF-6D/EQ-5D): 1.1–1.8) in health. The SF-6D did not respond well to deterioration in patients with established severe RA (ES and SRM 0.08). The EQ-5D provided larger absolute mean change estimates but with greater variance compared to the SF-6D.
The comparative responsiveness of the EQ-5D and SF-6D differs according to the direction of change. The level of mean change of the EQ-5D relative to the SF-6D has implications for cost-effectiveness analysis. Use of the SF-6D in patients with severe progressive disease may be inappropriate.
Drummond, M. F., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005). Methods for the economic evaluation of health care programmes (3rd ed.). Oxford: Oxford University Press.
National Institute for Health and Clinical Excellence. (2005). A guide to NICE. London: National Institute for Clinical Excellence.
Ontario Ministry of Health and Long-Term Care. (2007). Ontario guidelines for economic analysis of pharmaceutical products. Internet 2004 August [cited 2007 Jan 31];Available from: URL: http://www.health.gov.on.ca/english/providers/pub/drugs/economic/economic_mn.html.
Sullivan, S. D., Lyles, A., Luce, B., & Grigar, J. (2001). AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefits management organizations. Journal of Managed Care Pharmacy,7(4), 272–282.
NICE. (2004). Guide to the methods of technology appraisal. London: National Institute for Clinical Excellence. Ref Type: Pamphlet.
Harrison, M. J., Davies, L. M., Bansback, N. J., Ingram, M., Anis, A. H., & Symmons, D. P. (2008). The validity and responsiveness of generic utility measures in rheumatoid arthritis: A review. The Journal of Rheumatology,35(4), 592–602. PubMed
Russell, A. S., Conner-Spady, B., Mintz, A., Mallon, C., & Maksymowych, W. P. (2003). The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab. The Journal of Rheumatology,30(5), 941–947. PubMed
Verstappen, S. M. M., McCoy, M. J., Roberts, C., Hassell, A. B., Dale, N. E., & Symmons, D. P. M. (2008). A 3 week course of IM steroid injection may prevent the progression of very early inflammatory polyarthritis: Results of the STIVEA trial. Annals of the Rheumatic Diseases,67(Suppl II), 61.
Symmons, D., Tricker, K., Harrison, M., Roberts, C., Davis, M., Dawes, P., et al. (2006). Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs—results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial. Rheumatology (Oxford),45, 558–565. CrossRef
Silman, A., Symmons, D., Scott, D. G., & Griffiths, I. (2003). British society for rheumatology biologics register. Annals of the Rheumatic Diseases,62(Suppl 2), ii28–ii29. PubMed
The EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy,16(3), 199–208. CrossRef
Prevoo, M. L. L., Vanthof, M. A., Kuper, H. H., Vanleeuwen, M. A., Vandeputte, L. B. A., & Vanriel, P. L. C. M. (1995). Modified disease-activity scores that include 28-joint counts—development and validation in a prospective longitudinal-study of patients with rheumatoid-arthritis. Arthritis and Rheumatism,38(1), 44–48. PubMedCrossRef
Wiles, N. J., Lunt, M., Barrett, E. M., Bukhari, M., Silman, A. J., Symmons, D. P., et al. (2001). Reduced disability at five years with early treatment of inflammatory polyarthritis: Results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis and Rheumatism,44(5), 1033–1042. PubMedCrossRef
Verstappen, S. M., Jacobs, J. W., Bijlsma, J. W., Heurkens, A. H., van Booma-Frankfort, C., Borg, E. J., et al. (2003). Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis and Rheumatism,48(7), 1797–1807. PubMedCrossRef
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., et al. (1999). Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Annals of Internal Medicine,130(6), 478–486. PubMed
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., et al. (1999). Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet,354(9194), 1932–1939. PubMedCrossRef
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., et al. (2003). Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis and Rheumatism,48(1), 35–45. PubMedCrossRef
Hider, S. L., Buckley, C., Silman, A., Symmons, D. P. M., & Bruce, I. N. (2004). Factors influencing response to disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis. The Journal of Rheumatology (in press).
Cohen, J. (1977). Statistical power analysis for the behavioural sciences. New Jersey: Lawrence Earlbaum.
Scott, D. L., Smith, C., & Kingsley, G. (2003). Joint damage and disability in rheumatoid arthritis: An updated systematic review. Clinical and Experimental Rheumatology,21(5 Suppl 31), S20–S27. PubMed
Steiger, J. H. (1980). Tests for comparing elements of a correlation matrix. Psychological Bulletin,87(2), 245–251. CrossRef
Meng, X. L., Rosenthal, R., & Rubin, D. B. (1992). Comparing correlated correlation-coefficients. Psychological Bulletin,111(1), 172–175. CrossRef
Liang, M. H. (2000). Longitudinal construct validity: Establishment of clinical meaning in patient evaluative instruments. Medical Care,38(9 suppl), II84–II90. PubMed
Wells, G. A., Tugwell, P., Kraag, G. R., Baker, P. R., Groh, J., & Redelmeier, D. A. (1993). Minimum important difference between patients with rheumatoid arthritis: The patient’s perspective. The Journal of Rheumatology,20(3), 557–560. PubMed
Kosinski, M., Zhao, S. Z., Dedhiya, S., Osterhaus, J. T., & Ware, J. E, Jr. (2000). Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis and Rheumatism,43(7), 1478–1487. PubMedCrossRef
- The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis
M. J. Harrison
L. M. Davies
N. J. Bansback
M. J. McCoy
S. M. M. Verstappen
D. P. M. Symmons
The British Society for Rheumatology Biologics Register Control Centre Consortium, on behalf of the BSRBR
- Springer Netherlands